CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 42 enrolled
Drug / intervention
Transdermal estradiol +3 moredrug
Likely dose
Transdermal estradiol 50 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00066157
NCT00066157Phase 3Completed
CompareCT.gov

Alzheimer's Disease: Therapeutic Potential of Estrogen

University of Wisconsin, Madison·interventional·Posted Aug 5, 2003·Updated Aug 23, 2018

In Brief

A Phase 3 clinical trial evaluating Transdermal estradiol, Medroxyprogesterone, and 2 other interventions for Alzheimer Disease. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 5, 2003
Enrollment StartSep 1, 2001
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 22.9 years ago

Interventions

Transdermal estradioldrug

50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months

Medroxyprogesteronedrug

2.5mg tablet daily for 12 months

Placebo Patchdrug

Transdermal placebo patch, changed every 3 days, for 12 months

Placebodrug

Placebo tablet daily for 12 months